Technical Analysis for BCAX - Bicara Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | -1.96% | |
| Narrow Range Bar | Range Contraction | -1.96% | |
| Wide Bands | Range Expansion | -1.96% | |
| Oversold Stochastic | Weakness | -1.96% | |
| NR7 | Range Contraction | -1.55% | |
| Narrow Range Bar | Range Contraction | -1.55% | |
| Doji - Bullish? | Reversal | -1.55% | |
| New 52 Week Low | Weakness | -1.55% | |
| Wide Bands | Range Expansion | -1.55% | |
| Oversold Stochastic | Weakness | -1.55% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Up 3% | about 1 hour ago |
| Down 1% | about 1 hour ago |
| Up 2% | about 1 hour ago |
| Up 1% | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: Unknown
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Antibodies Tumor Cancer Immunotherapy Epidermal Growth Factor Receptor Specialty Drugs Tyrosine Kinase Receptors Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Antibodies Tumor Cancer Immunotherapy Epidermal Growth Factor Receptor Specialty Drugs Tyrosine Kinase Receptors Tumor Microenvironment
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.08 |
| 52 Week Low | 11.51 |
| Average Volume | 416,343 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 17.85 |
| 20-Day Moving Average | 15.15 |
| 10-Day Moving Average | 12.83 |
| Average True Range | 1.26 |
| RSI (14) | 25.93 |
| ADX | 34.22 |
| +DI | 10.20 |
| -DI | 30.72 |
| Chandelier Exit (Long, 3 ATRs) | 15.97 |
| Chandelier Exit (Short, 3 ATRs) | 15.29 |
| Upper Bollinger Bands | 20.33 |
| Lower Bollinger Band | 9.96 |
| Percent B (%b) | 0.19 |
| BandWidth | 68.44 |
| MACD Line | -1.87 |
| MACD Signal Line | -1.66 |
| MACD Histogram | -0.2134 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.89 | ||||
| Resistance 3 (R3) | 12.83 | 12.48 | 12.73 | ||
| Resistance 2 (R2) | 12.48 | 12.24 | 12.50 | 12.68 | |
| Resistance 1 (R1) | 12.22 | 12.10 | 12.35 | 12.28 | 12.63 |
| Pivot Point | 11.87 | 11.87 | 11.93 | 11.89 | 11.87 |
| Support 1 (S1) | 11.61 | 11.63 | 11.74 | 11.67 | 11.31 |
| Support 2 (S2) | 11.26 | 11.49 | 11.28 | 11.26 | |
| Support 3 (S3) | 11.00 | 11.26 | 11.21 | ||
| Support 4 (S4) | 11.06 |
